Qiagen Liabilities 2024

Qiagen Aktienanalyse

What does Qiagen do?

Qiagen NV is a biotechnology company based in Venlo, Netherlands. The company was founded in 1984 as a spin-off from the University of Düsseldorf and has since become a leading provider of molecular diagnostic products and systems. Qiagen operates in four business areas: Life Sciences, Molecular Diagnostics, Applied Testing, and Pharma. Life Sciences is the largest business area of the company and offers a wide range of products for DNA sequencing, gene expression, RNA isolation and analysis, as well as protein analysis. Molecular Diagnostics specializes in diagnostic tests for diseases such as cancer, infections, and genetic disorders. Applied Testing provides solutions for forensic analysis and food and environmental analysis, while Pharma offers products and services for drug discovery and development. In recent years, Qiagen has focused mainly on the development of molecular diagnostic tests for cancer and infection-related diseases such as HIV, hepatitis, and tuberculosis. These tests enable earlier detection of diseases and more targeted therapy, improving patient care and reducing healthcare costs. One example of a successful Qiagen product is the Cobas HPV Test, a molecular diagnostic test for the detection of human papillomaviruses (HPV) responsible for cervical cancer. The test is distributed by Roche Diagnostics and is one of the best-selling molecular diagnostic tests in the world. Qiagen also has a strong presence in academic research and is a major provider of tools and technologies for DNA sequencing and genome research. Customers include leading research institutes, universities, and pharmaceutical companies. In recent years, Qiagen has also expanded through acquisitions to expand its offering of products and technologies and enter new markets. For example, in 2018, the company acquired N-of-One, a provider of artificial intelligence in cancer diagnostics, and NeuMoDx Molecular, a provider of molecular diagnostic platforms for laboratories. In 2020, Qiagen also played a crucial role in the development of tests for the new coronavirus (SARS-CoV-2). The company, together with other leading diagnostic companies, developed molecular diagnostic tests for rapid and reliable diagnosis of COVID-19. Overall, Qiagen is an important player in the biotech industry, offering a wide range of products and services for molecular diagnostics, genome research, and pharmaceutical research. Qiagen has a strong competitive position due to its innovative products and technologies, strong presence in academic research, and strategic acquisitions to expand its product portfolio and market access. Qiagen ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Qiagen's Liabilities

Qiagen's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Qiagen's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Qiagen's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Qiagen's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Qiagen’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Qiagen Stock

What is the level of liabilities of Qiagen this year?

Qiagen has a debt balance of 2.31 B USD this year.

What were the liabilities of Qiagen compared to the previous year?

The liabilities of Qiagen have increased by -18.21% dropped compared to the previous year.

What are the consequences of high debt for investors of Qiagen?

High liabilities can pose a risk for investors of Qiagen, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Qiagen?

Low liabilities mean that Qiagen has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Qiagen affect the company?

An increase in liabilities of Qiagen can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Qiagen affect the company?

A decrease in the liabilities of Qiagen can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Qiagen?

Some factors that can influence the liabilities of Qiagen include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Qiagen so important for investors?

The liabilities of Qiagen are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Qiagen take to modify the liabilities?

To change its liabilities, Qiagen can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Qiagen pay?

Over the past 12 months, Qiagen paid a dividend of 1.08 USD . This corresponds to a dividend yield of about 2.38 %. For the coming 12 months, Qiagen is expected to pay a dividend of 0 USD.

What is the dividend yield of Qiagen?

The current dividend yield of Qiagen is 2.38 %.

When does Qiagen pay dividends?

Qiagen pays a quarterly dividend. This is distributed in the months of February, February, February, February.

How secure is the dividend of Qiagen?

Qiagen paid dividends every year for the past 5 years.

What is the dividend of Qiagen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Qiagen located?

Qiagen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Qiagen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Qiagen from 2/1/2024 amounting to 1.32 USD, you needed to have the stock in your portfolio before the ex-date on 1/30/2024.

When did Qiagen pay the last dividend?

The last dividend was paid out on 2/1/2024.

What was the dividend of Qiagen in the year 2023?

In the year 2023, Qiagen distributed 0 USD as dividends.

In which currency does Qiagen pay out the dividend?

The dividends of Qiagen are distributed in USD.